EZH2 gain-of-function mutations and overexpression lead to aberrant H3K27me3 levels and result in tumorigenesis and metastasis.4–7 The gain-of-function point mutations in EZH2 have been found in over 20% diffuse large B-cell lymphoma (DLBCL) and 27% of follicular lymphoma (FL) patients.8,9 These mutations were considered as early clonal events in lymphomagenesis and are capable of sustaining disease progression. Here, EZH2 is linked to diffuse large B-cell lymphoma.